FORM 4	1
--------	---

Check this box if no	
longer subject to	
Section 16. Form 4 or	
Form 5 obligations	
may continue. See	1
Instruction 1(b).	

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

OMB APPROVAL OMB 3235-Number: 0287 Estimated average burden hours per 0.5 response...

(9-02)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)											
1. Name and Addres Zaderej Karen L.	2. Issuer Name <b>and</b> Ticker or Trading Symbol AxoGen, Inc. [AXGN]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) ( C/O AXOGEN, II PROGRESS BOU 100		3. Date of Earliest Transaction (Month/Day/Year) 08/14/2013						X_ Officer (give title Other (specify below) below) Chief Executive Officer			
(City) (City)		4. If Amendment, Date Original Filed(Month/Day/Year)					-	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person irred, Disposed of, or Beneficially Owned			
1.Title of Security (Instr. 3)		Exec any	Deemed ution Date, if hth/Day/Year)	3. Transact Code	tion	4. Securi Acquired Disposed (Instr. 3, Amount	ities 1 (A) d of (I 4 and (A) or	or D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form:	7. Nature of Indirect Beneficial Ownership
Common Stock	08/14/2013	08/1	4/2013	Р		8,334 <u>(1)</u>	А	\$3	129,124	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

#### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned - 4.

	( <i>e.g.</i> , puts, calls, warrants, options, convertible securities)													
1. Title of	2.	3. Transaction	3A. Deemed	4.	5.		6. Date Exe	rcisable	7. Tit	le and	8. Price of	9. Number of	10.	11. Nature
Derivative	Conversion	Date	Execution Date, if	Transaction	n Nu	nber	and Expirati	on Date	Amo	unt of	Derivative	Derivative	Ownership	of Indirect
Security	or Exercise	(Month/Day/Year)	any	Code	of		(Month/Day	/Year)	Unde	erlying	Security	Securities	Form of	Beneficial
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Der	ivative			Secu	rities	(Instr. 5)	Beneficially	Derivative	Ownership
	Derivative				Sec	urities			(Inst	r. 3 and		Owned	Security:	(Instr. 4)
	Security				Aco	quired			4)			Following	Direct (D)	
					(A)	or						Reported	or Indirect	
						posed						Transaction(s)	(I)	
					of (							(Instr. 4)	(Instr. 4)	
					`	str. 3,								
					4, a	nd 5)								
										Amount				
							Date	Expiration		or				
							Exercisable		Title	Number				
							Excretisable	Date		of				
				Code V	(A)	(D)				Shares				

## **Reporting Owners**

Beneuting Owner Name / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Zaderej Karen L. C/O AXOGEN, INC. 13859 PROGRESS BOULEVARD, SUITE 100 ALACHUA, FL 32615	х		Chief Executive Officer					

# Signatures

/s/ Karen Zaderej	08/15/2013
Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The reporting person purchased these shares in its individual capacity and not through any directed share or other formal program in connection with an underwritten registered public offering of the Company. On August 9, the trade date for the public offering and the first day AxoGen shares were traded on the NASDAQ Capital Market, the closing sale price reported by NASDAQ was \$2.98 per share. The public offering closed on August 14, 2013, and the closing sale price reported by NASDAQ on August 14, 2013 was \$2.97 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.